Eli Lilly and Company (LLY)

NYSEHealthcare

$935.62
-$18.89 (-2.0%)
Market closed

April 2, 2026 at 20:00 UTC

Interactive Chart

LLY
1H
3H
6H
12H
1D
1W
1M
3M
6M
1Y
2Y
5Y
All

13:25:36 UTC

About Eli Lilly and Company

Name
Eli Lilly and Company
CEO
David A. Ricks
Industry
Healthcare
Year Founded
1876
Employees
47,000

Eli Lilly and Company is a pharmaceutical manufacturer that discovers, develops, and supplies medicines for conditions managed over long periods and in specialized care. The model connects science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use in clinics and hospitals. The company’s priority is continuity — steady supply, clear labeling, and guidance that helps clinicians match therapy to patients. Access programs and country teams adapt to local frameworks while holding to shared safety standards. Digital tools and field support aim to simplify onboarding and monitoring without adding burden to care teams. Within the healthcare sector, Lilly’s role is to make new options feel dependable in daily practice, while continuing to invest in pipelines that can address unmet medical need.

Analyst Ratings

Consensus Recommendation
Analyst consensus: 5 Buy, 11 Hold, 7 Sell
Buy5
Hold11
Sell7

Fundamentals & Financials

Revenue (TTM)
$65.1B
Net Income (TTM)
$20.6B
EPS (TTM)
$23
ROA (TTM)
18.35%
Current Ratio
1.58
Dividend Yield
0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

ItemQ4 2025
Revenue$19,292M
Cost of Sales$2,883.7M
Gross Profit$16,408.3M
Operating Income$8,775.3M
Net Income$6,636M
EPS$7.41

Technical Indicators

Eli Lilly and Company's Technical Indicators Summary

Eli Lilly presents a mixed technical profile with the market above the 10-day and significantly above the 200-day averages, yet below several medium-term moving averages, and the pivot sits above current price. Momentum is positive on the short look while MACD is noncommittal, and ADX signals a modest trend without strong conviction; ATR shows moderate volatility. OBV is lower, indicating weaker volume support for recent gains. Technical takeaway: the technical state is neutral with short-term strength offset by mixed medium- and long-term signals.

Buy
5 signals
Neutral
11 signals
Sell
7 signals
Overall: Neutral48% Neutral signals
IndicatorValue
RSI (14)
46.28
Stochastic %K (14, 3, 3)
47.84
CCI (20)
-2.38
WPR (14)
-51.70
Momentum (10)
18.08
MFI
43.27
MACD Level (12, 26)
-24.75
Bollinger Bands
$856.06 - $1026.49
ATR (14)
$29.23 (3.12%)
ADX (14)
21.97
OBV
93,277,600
Classic Pivot Point
$952.40
Fibonacci Pivot Point
$952.40
Exponential Moving Averages
$901.05 - $976.64(5 indicators)
Simple Moving Averages
$897.92 - $1022.37(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

End-of-day sector performance was slightly negative (-0.62%), mildly offsetting stock-specific strength. End-of-day, LLY remains on track for an upcoming update on 30 April, roughly 27 days away. LLY edges higher on FDA approval for Foundayo weight-management pill, ahead of its April 30 update.

Price Change

from $935.62 close

+$0.39

Trading Volume

Below avg (3.3M)

2.7M

vs S&P 500 Today

Strong Underperformance

-19.05%

52-Week Position

Mid-range

61.1%

Updated: April 3, 2026 at 20:02 UTC

Quote Summary

OpenPrevious Close
$945$935.62
Day Range52 Week Range
$930.02 - $957.69$623.78 - $1133.95
VolumeAvg. Volume
2.7M3.2M
Market CapP/E Ratio
$883.9B40.8